Figure 1:. ADCC efficacy against WM cells for GA101 versus rituximab using healthy donor or autologous NK cells genotyped for FcγRIIIA-158.
Figure 1:

ADCC efficacy against WM cells for GA101 versus rituximab using healthy donor or autologous NK cells genotyped for FcγRIIIA-158.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal